Radiology injection

Product Details:

Iomeron®

Iomeron® is a tri-iodinated non-ionic monomeric contrast medium for radiology7

When highest iodine concentration matters1,2,3,4,5,6Iomeron® has interesting favorable properties, such as

the lowest viscosity at given concentration among iso-osmolar contrast media (IOCM) and low-osmolar contrast media (LOCM)7;

the lowest osmolality among monomeric LOCM7;

one formulation with the highest iodine concentration (400 mgI/mL) available on the market.

An injectable solution at a higher iodine concentration allows a greater peak of enhancement in a shorter time from the injection when injected at the same volume and flow rate compared to a solution at a lower iodine concentration8.

Iomeron® (Iomeprol) is Bracco's latest generation contrast agent. Launched in 19959, this tri-iodinated non-ionic contrast agent has quickly become the preferred choice for many practicing clinicians9. Its unique and innovative profile can boast the highest concentration (400 mgI/mL), nonionic agent ever approved in the world10.

Iomeprol is currently registered in more than 40 countries worldwide, including all major European & Middle Eastern countries, Japan and the Asian Pacific. This agent represents a step forward in its class. Iomeprol has become the number one choice for many clinicians for many reasons – including:

a unique product that combines the lowest viscosity among non-ionic agents and a very low osmolality compared to other available nonionic monomeric agents10;

Iomeron® is readily available in a wide variety of iodine concentration and volumes for clinical use;

in first pass dynamic CT imaging, at equal flow rate and total iodine dose, Iomeprol 400 mgI/mL, can provide better contrast enhancement and image quality than contrast solutions at lower iodine strength11,12,13;

in a multicenter, randomized, double-blind, parallel-group comparison of Iomeron and iodxanol in coronary CTA, observed mean heart rate changes after intravenous contrast injection were generally small during the examination and comparable for Iomeron-400 and iodixanol 32014;

a prospective intra-individual study showed that a low-dose radiation exposure acquisition protocol, in conjunction with the use of Iomeron-400, provides substantially reduced radiation exposure while maintaining a constant CNR and good image quality compared to a standard protocol using a lower concentrated contrast medium in CTA examinations15;

a large study compared the effects of Iomeprol-400 and Iodixanol-320 on kidney function in patients with pre-existing chronic kidney diseases (CKD) undergoing CT examinations. Based on the results, the authors of the study concluded: "The incidence of CIN was significantly higher after the IV administration of iodixanol-320 than iomeprol-400 in patients with moderate-to-severe CKD. The mean increase in SCr from baseline was also higher in patients receiving iodixanol. Characteristics of the individual contrast agents other than osmolality may be important in causing nephrotoxicity" 16.

Product Details:

GADOTERATE MEGLUMINE (gad oh TER ate MEG loo meen) is a contrast agent. It is used to diagnose abnormalities during a MRI.